<DOC>
	<DOC>NCT00102193</DOC>
	<brief_summary>The purpose of this study is to demonstrate the safety and effectiveness of the Adacolumn Apheresis System to treat the signs and symptoms of ulcerative colitis.</brief_summary>
	<brief_title>Study for the Treatment of Ulcerative Colitis With Adacolumn</brief_title>
	<detailed_description>Trial Features: - Non-drug therapy - Most patients can remain on current treatment regimen, including prednisone, budesonide and medications such as Asacol (mesalamine), Pentasa (mesalamine), Colazal (balsalazide disodium) and Dipentum (olsalazine sodium) throughout the study Components of the Study: - Study length is 24 weeks, which includes a screening visit, ten treatment visits over nine weeks and 4 follow-up appointments - Physical exams, laboratory tests and disease assessments conducted at no charge to the patient - 2:1 Randomization (treatment:sham)</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Moderate to severe active ulcerative colitis with colonic involvement with ulcerative colitis beyond 15 cm of the anal verge Adequate peripheral venous access to allow for completion of the apheresis treatments Receiving one or more of the following medical therapies: *sulfasalazine, *mesalamine and other 5ASA agents, *prednisone or 6mercaptopurine or azathioprine OR Have not received the above medical therapies due to intolerance or demonstrated nonresponse Agree to participate in the required followup visits Able to complete a diary Signed written informed consent document and authorization for use of protected health information Key Evidence of toxic megacolon Major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouchanal anastomosis Requiring inpatient hospitalization A history of allergic reaction to heparin or heparininduced thrombocytopenia A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures A history of severe cardiovascular or peripheral arterial diseases A history of cerebral vascular diseases Liver diseases Renal insufficiency Insulindependent Type I or Type II diabetes Known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment Any hypercoagulable disorder Known infection with Hepatitis B or C, or HIV Severe anemia Leukopenia or granulocytopenia Evidence of current systemic infection Malignancy Pregnant, lactating or planning to become pregnant during the course of the investigational study Used within the last 30 days, an investigational drug, biologic or device or 5 halflives, if known, for any investigational drug or biologic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Ulcerative Colitis, Apheresis</keyword>
</DOC>